Floatz logo

Octreotide Pamoate

Pancreatic Neoplasms

University of LiverpoolPhase 3Dormant
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
53/ 100
Competitive Position
81/ 100

Competitive context

382 Active assets in the Pancreatic Neoplasms cohort.

Asset / SponsorPhaseRating
Tinzaparin
Helsinki University Central Hospital
Phase 4BBB
CIS-DIAMMINEDICHLOROPLATINUM II
Taiho Oncology, Inc.
Phase 3BB
Eloxatin
Memorial Sloan Kettering Cancer Center
Phase 3BB
FLUOROURACILUM
Memorial Sloan Kettering Cancer Center
Phase 3BB
Capecitabine
Tianjin Medical University Cancer Institute and Hospital
Phase 3BB

View all 50 →

Same molecule, other indications

Octreotide Pamoate is also rated in:

diarrheal diseaseDormant
BB
Indicative ·
71 / 100
View asset →
cirrhosis of liverDormant
BB
Indicative ·
71 / 100
View asset →
esophageal varicesDormant
BB
Indicative ·
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →